MDR and IVDR
MDR and IVDR: from classification to certification and market surveillance
Regulations (EU) 2017/745 and 2017/746 define what a manufacturer must demonstrate to affix the CE mark — and what must be monitored for as long as the device stays on the market. We build the technical documentation, guide you through conformity assessment and set up post-market surveillance.
Technical documentation
Documentation that survives notified body review
We prepare technical documentation for medical devices and in vitro diagnostics in line with applicable regulatory standards and in the structure notified bodies expect.
The most common reason for review questions is not a missing document but inconsistency: the intended purpose in the IFU differs from the one in the clinical evaluation, or the risk analysis does not reflect actual use.
- Device description, variants, accessories and intended purpose
- General safety and performance requirements
- Risk analysis and benefit/risk assessment
- Clinical evaluation and performance evaluation
- Design verification and validation, biological safety
- Information supplied to the user — labelling and IFU
- Clinical investigation documentation
- Post-market surveillance plan and reports
The simplification proposal (2025/0404(COD)) is in first reading, the lead European Parliament committee is SANT and the rapporteur is Oliver Schenk. Neither institution has a trilogue mandate and adoption before 2027 is not realistic. Relaxing existing compliance processes in anticipation is not advisable.
Since 2026 the Czech regulator offers a formalised pre-regulatory channel for innovative devices, IVDs and medical software — covering qualification, classification, clinical evaluation and the conformity assessment route.
FAQ
Questions we hear most
Answers reflect the rules and decision practice as of September 2026.
How do we determine our device class?
Classification follows the rules in Annex VIII of MDR (Annex VIII of IVDR for in vitro diagnostics) and depends on intended purpose, duration of body contact, invasiveness and risk. Borderline products — software, combination products, items near cosmetics or medicinal products — are where it gets difficult.
For borderline cases we recommend documenting the reasoning in writing and, where genuinely unclear, using a pre-regulatory consultation before the decision is baked into the technical file.
Can we reuse documentation prepared under the old directives?
Not unchanged. MDR and IVDR expand requirements particularly on clinical evidence, risk analysis and post-market surveillance. Documentation under MDD, AIMDD or IVDD is a starting point, but the clinical evaluation and PMS system typically need rebuilding.
When do we need an authorised representative?
A manufacturer established outside the EU must appoint an EU authorised representative. It performs defined manufacturer duties towards authorities and appears on the labelling and in the registration.
Note Article 16: placing a device on the market under your own name or trade mark can transfer the full set of manufacturer obligations to you.
Related
Services that connect to this one
Need documentation that passes first time?
Send us what you have. We will tell you what is missing, what is inconsistent and in what order to fix it.